Zufe Rizvi
Neurology · Houston, TXNPI 1588126932
Payments from drug & device makers
Across 158 payments — averaging $104.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Abbott$1K
- Boston Scientific$873
- AbbVie$817
- Amneal Pharmaceuticals LLC$253
- UCB, Inc.$227
- plus $2K from 25 others
What the payments were for
- Grants$10,00061%
- Travel & lodging$2,47915%
- Food & beverage$3,93224%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $11,376 |
| Abbott | 11 | $1,267 |
| Boston Scientific | 6 | $873 |
| AbbVie | 38 | $817 |
| Amneal Pharmaceuticals LLC | 9 | $253 |
| UCB, Inc. | 10 | $227 |
| Acadia Pharmaceuticals Inc | 5 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| EMD Serono, Inc. | 3 | $133 |
| Merz Pharmaceuticals, LLC | 6 | $109 |
| Neurocrine Biosciences, Inc. | 5 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| CSL Behring | 5 | $99 |
| Stryker | 1 | $97 |
| Ipsen Biopharmaceuticals, Inc | 3 | $88 |
| Lundbeck LLC | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 1 | $73 |
| AstraZeneca | 4 | $71 |
| SK Life Science, Inc. | 1 | $50 |
| Genentech USA, Inc. | 2 | $42 |
| MDD US Operations, LLC | 2 | $40 |
| Eisai Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| C2n Diagnostics, LLC | 1 | $24 |
| Biogen | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Novartis | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
| Aucta Pharmaceuticals, Inc. | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,484 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 47 | $88,164 |
| NeuproRotigotine | 11 | $25,374 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 101 | $3,399 |
| RivastigmineRivastigmine Tartrate | 30 | $2,216 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 50 | $2,120 |
| Rivastigmine | 11 | $1,774 |
| AmantadineAmantadine Hcl | 26 | $982 |
| Gabapentin | 32 | $816 |
| Mirtazapine | 17 | $425 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 14 | $408 |
| Escitalopram Oxalate | 22 | $334 |
| Propranolol Hcl | 11 | $256 |
| Sertraline Hcl | 20 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $253 | $88,16447 claims |
| UCB, Inc.Neupro | $227 | $25,37411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.